CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.

The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical countermeasures to improve patient outcomes and reduce the strain on healthcare systems. Current treatment options, especially for severe cases, are limited, resource-intensive, and often ineffective, highlighting the critical need for novel therapeutic approaches to combat the ongoing pandemic.

The Technology: Our groundbreaking technology leverages liponucleotides (LPNs) - CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol - essential precursors for the de novo production of phospholipids. LPN synthesis, crucial for maintaining cell membrane integrity, is inhibited by SARS CoV-2 and influenza A virus infections. The application of LPNs has shown remarkable efficacy in preclinical models, preventing hypoxemia, improving lung function, and reducing inflammation in late-stage acute respiratory distress syndrome (ARDS) induced by influenza. This breakthrough technology demonstrates unprecedented antiviral effects against SARS CoV-2, presenting a promising avenue for therapeutic intervention.

Commercial Applications:

  • Treatment of COVID-19 patients with severe respiratory complications
  • Prophylactic use to prevent the development of hypoxemia in high-risk individuals
  • Adjuvant therapy in combination with existing antivirals, antibodies, or corticosteroids
  • Potential application in the treatment of other respiratory infections and viral outbreaks
  • Integration into comprehensive infection control strategies for healthcare facilities


  • Unprecedented antiviral activity against SARS CoV-2, addressing a critical gap in current treatment options
  • Attenuation of viral replication and reduction of inflammatory markers, improving cardiopulmonary function
  • Potential to reduce the severity of respiratory complications and improve patient outcomes
  • Versatile application as both a standalone treatment and in combination with existing therapeutic modalities
  • Contribution to infection control measures, offering a proactive approach to managing respiratory infections and future viral outbreaks

In summary, our cutting-edge technology provides a transformative solution to the pressing challenges posed by the SARS CoV-2 pandemic, offering a unique and effective approach to the treatment and prevention of COVID-19 and other respiratory infections.

Loading icon